Table 5.

SPC occurrence following pancreatic IPMN stratified by latency.

	6–11 months				12–59 months				60–119 months				120+ months
	O	SIR	95% CI	ER	O	SIR	95% CI	ER	O	SIR	95% CI	ER	O	SIR	95% CI	ER
All sites	18	1.06	0.63–1.67	8.74	56	1.06	0.80–1.38	10.05	34	1.49	1.03–2.08	84.35	10	2.25	1.08–4.14	194.49
All solid tumors	16	1.06	0.60–1.72	7.79	48	1.03	0.76–1.36	3.92	32	1.60	1.09–2.25	90.51	10	2.58	1.24–4.75	214.28
Oral cavity and pharynx	1	2.53	0.06–125.67	−0.27	3	2.43	0.50–7.10	5.38	1	1.86	0.05–10.36	3.50	0
Digestive system	3	0.90	0.19–2.63	−2.98	12	1.16	0.60–2.03	5.10	9	1.96	0.90–3.73	33.45	3	3.33	0.69–9.73	73.41
Respiratory system	0				7	0.81	0.32–1.68	−5.10	8	2.10	0.90–4.13	31.67	3	4.14	0.85–12.11	79.62
Breast	2	1.03	0.12–3.72	0.53	3	0.57	0.12–1.67	−6.90	2	1.01	0.12–3.66	0.19	1	2.10	0.05–11.87	18.57
Female genital System	1	1.35	0.03–7.51	2.34	1	0.50	0.01–2.76	−3.10	0				0
Male genital system	7	2.24	0.90–4.62	35.20	8	0.80	0.34–1.57	−6.16	2	0.49	0.06–1.78	−15.57	1	1.59	0.04–8.84	12.94
Urinary system	1	0.65	0.02–3.65	−4.78	6	1.19	0.44–2.60	2.97	8	3.33	1.44–6.56	42.37	1	2.15	0.05–12.00	18.74
Brain and other nervous system	0				1	1.89	0.05–10.55	1.44	0				0
endocrine system	1	4.27	0.11–23.80	6.95	2	2.77	0.34–10.00	3.89	0				0
All Lymphatic and hematopoietic diseases	2	1.37	0.17–4.94	4.88	6	1.29	0.47–2.81	4.13	1	0.46	0.01–2.57	−8.88	0